At a glance
ClinicalIndex Comparison RecordN/ACompleted· 150 enrolled
Drug / intervention
Recombinant tuberculosis allergen (RTA)other
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Specificity of Intradermal Test With Recombinant Tuberculosis Allergen in BCG Vaccinated Healthy Volunteers
National Medical Research Center of Phthisiopulmonology and Infectious Diseases·interventional·Posted Jan 24, 2022·Updated Aug 25, 2023
In Brief
A clinical study evaluating Recombinant tuberculosis allergen (RTA) for Tuberculosis. Completed, enrolled 150 participants across 1 site.
Detailed Summary
The aim of this study is to test the recombinant tuberculosis skin test in the previously BCG vaccinated healthy adults with low risk of TB development, to determine the test specificity.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTuberculosis
CountriesRussia
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
Enrollment StartNov 2021
Primary CompletionJan 2022
First PostedJan 2022
Study CompletionJan 2022
TodayJul 2026
First PostedJan 24, 2022
Enrollment StartNov 24, 2021
Primary CompletionJan 18, 2022
Study CompletionJan 26, 2022
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 4.4 years ago
Interventions
Recombinant tuberculosis allergen (RTA)other
Single intradermal application of 0.2 µg/0.1 mL RTA (CFP10-ESAT6) in the middle of the forearm